The Upstarts Podcast Loyal’s Celine Halioua: From Defying Doubters To Pioneering Dog Longevity
14 snips
Feb 19, 2026 
Celine Halioua, founder and CEO of Loyal who raised major funding to pursue canine longevity, shares her journey from neuroscience to building drugs that could extend dogs' healthspan. She talks about running a massive 1,300-dog FDA trial. She explains why dogs are a faster path than humans, the portfolio strategy of multiple drug programs, and the challenge of changing investor pattern-matching.
AI Snips
Chapters
Transcript
Episode notes
A Hybrid Company Defies Pattern Matching
- Loyal sits at the intersection of biotech and consumer product culture, making it hard to pattern-match.
- That hybrid identity creates both recruitment challenges and unique advantages in market positioning.
Running The Largest Canine Trial
- Loyal is running a 1,300-dog clinical trial, the largest ever in companion animals in the U.S.
- The FDA requires rigorous proof of efficacy, safety, and reliable manufacturing for animal drugs just like human drugs.
Make Safety The First Priority
- Prioritize safety above novelty for preventive drugs given you treat healthy animals.
- Choose molecules with an extremely high safety profile and gather robust data to satisfy regulators.